ONCOLYTICS BIOTECH INC (ONCY)

Company Profile

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Company Info

ONCOLYTICS BIOTECH INC

804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7

Calgary ALBERTA T2N 1X7

P: 14036707377

CEO: Matthew C. Coffey

Employees: 29

Website: https://www.oncolyticsbiotech.com/